Tislelizumab NSCLC Inclusion Recommended for Du...

By HEOR Staff Writer

February 9, 2026

Tislelizumab NSCLC Inclusion in Dutch Basic Package Zorginstituut Nederland's Tislelizumab NSCLC Inclusion Recommendation Zorginstituut Nederland's advis...
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
Ozempic Public Funding Approval in Portugal: Key Insights and Implications
Surge in Obesity Intervention Costs in the Netherlands
HPV Vaccination Benefits Portugal: A Cost-Benefit Analysis of Expansion Effects
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Characterizing Burnout in Health Professionals: Insights from the BEATS Study...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investmen...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management